Pharmaceutical

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lymphomas: Likelihood of Approval

CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.

Oct 3, 2023 - 20:00
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.
Read the original article

Tags:

Previous Article

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

Next Article

BGB-26808 by BeiGene for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Critics and defenders weigh in on Stanford president’s resignation after research investigation

Critics and defenders weigh in on Stanford president’s ...

Jul 20, 2023

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia

Botulinum battle heats up with FDA approving Daxxify fo...

Aug 14, 2023

STAT+: Nobel Prize, in a rarity, celebrates a fruitful and durable partnership

STAT+: Nobel Prize, in a rarity, celebrates a fruitful ...

Oct 2, 2023